Abstract
Riluzole is the only drug shown to slow the course of amyotrophic lateral sclerosis (ALS). Patients with ALS-associated dysphagia may have to discontinue riluzole therapy because of their inability to swallow the tablet formulation of the drug. An oral suspension of riluzole (Teglutik®) has recently been approved, which may allow patients with ALS-associated dysphagia to continue riluzole therapy for longer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
